Skip to main content
Careers
Contact us
Company
About Us
Management
Board of Directors
Advisory Board
Therapeutic Focus
Neurological Disorders
Chronic Pain
Hair Loss Disorders
Science and Technology
Exicure's Approach
References and Papers
Pipeline
Pipeline
Collaboration Programs
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
News
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
Pipeline
Pipeline
AST-008
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/14/2021
Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
12/10/2021
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus
11/19/2021
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
11/15/2021
Exicure Files Form 12b-25
10/28/2021
Exicure to Present at Upcoming Scientific Conferences
10/07/2021
Exicure to Present at Upcoming Scientific Conferences
10/04/2021
Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
09/23/2021
Exicure to Present at the Benzinga Healthcare Small Cap Conference
09/15/2021
Exicure to Participate in Upcoming Scientific Conferences
09/01/2021
Exicure to Participate in Upcoming Investor Conferences
08/12/2021
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress
08/05/2021
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
08/04/2021
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference
08/02/2021
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
07/08/2021
Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day
06/29/2021
Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference
06/03/2021
Exicure, Inc. Announces Participation in Upcoming Conferences
05/13/2021
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
05/12/2021
Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress
03/11/2021
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
03/11/2021
Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress
03/09/2021
Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors
03/03/2021
Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod
02/23/2021
Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
02/09/2021
Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference
02/02/2021
Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference
01/11/2021
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration
01/05/2021
Exicure Announces Appointment of James Sulat to Board of Directors
01/04/2021
Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day